Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reproductive Medicine and Biology
Published in: Reproductive Medicine and Biology 2/2015

01-04-2015 | Review Article

The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience

Author: Zdenka Ulcova-Gallova

Published in: Reproductive Medicine and Biology | Issue 2/2015

Login to get access

Abstract

Antiphospholipid antibodies (aPls) are generally characterized as heterogeneous and non-specific autoantibodies directed against various phospholipids such as cardiolipin, ph-serine, ph-inositol, ph-acid, ph-glycerol, ph-sphyngomyelin, ph-choline, annexins, and co-factor β2-glycoprotein I. aPls occur not only during autoimmune diseases but also during infectious diseases, essential hypertension, neurological complication, metabolic diseases, some drug abuse, and transplant loss. aPls are very often found in connection with reproductive failure such as repeated pregnancy loss and/or missed abortion, intrauterine fetal death, in preeclampsia, and repeated delivery of hypothrophic fetus. The presence of aPls, thrombosis, and fertility failure create primary or secondary antiphospholipid syndrome. This article explains some aspects and clinical and laboratory significance of the aPls in female infertility.
Literature
1.
Wasserman A. Über die Entwicklung und den gegenwärtigen Stand der Serodiagnostik gegenüber Syphilis. Berl Klin Wochenschr. 1907;44:1599–605.
2.
Pangborn MC. A new serologically active phospholipids from beef heart. Proc Soc Exp Biol Med. 1941;48:484–6.CrossRef
3.
Conley CL, Hartman RC. Haemorrhagic disorders caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–6.
4.
Laurell A, Nilsson IM. Hypergammaglobulinemia, circulating anticoagulant, and biologic false-positive Wasserman reaction. J Lab Clin Med. 1957;49:694–707.PubMed
5.
Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb. 1982;6:263–85.PubMed
6.
Harris EN, Ghavari AE, Boey ML. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211–4.CrossRefPubMed
7.
Loizou S, McCrea JD, Rudge AC. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardisation and quantitation of results. Clin Exp Immunol. 1985;62:738–45.PubMedCentralPubMed
8.
Harris EN, Gharavi AE, Wasley GD, Hughes GRV. Use of an enzyme-linked immunosorbent assay and inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis. 1988;157:23–31.CrossRefPubMed
9.
Koike T, Sueishi M, Funaki H. Antiphospholipid antibodies and biological false-positive serological tests for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol. 1984;56:193–9.PubMedCentralPubMed
10.
Olhoffer IH, Peng SL, Craft J. Revisiting autoantibody profiles in systemic lupus erythematosus. J Rheumatol. 1997;24:297–302.PubMed
11.
12.
McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49:193–279.CrossRefPubMed
13.
Asheron RA, Cervera R. Antiphospholipid antibodies and infectious. Ann Rheum Dis. 2003;49:388–93.CrossRef
14.
Vaarla O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75:456–9.
15.
Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.PubMed
16.
Briley DP, Coull BM, Goodnight SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. 1989;44:221–7.CrossRef
17.
Shoenfeld Y, Lev S, Blatt I. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–8.PubMed
18.
Singer HS, Krumholz A, Giuliano J, Kiessling LS. Antiphospholipid antibodies: an epiphenomenon in Tourette syndrome. Mov Disord. 1997;12:738–42.CrossRefPubMed
19.
Mori T, Takai Y, Minakuchi R. Inhibitory action of chlorpromazine, dibucaine and other phospholipid-interacting drugs on calcium-activated phospholipid-dependent protein kinase. J Biol Chem. 1980;225:8378–80.
20.
Chedid A, Kurmanadha CR, Morgan TR, Moritz TE, Mendenhall CL, Hammong JB. Antiphospholipid antibodies in alcoholic liver disease. Hepatology. 1994;31:141–2.
21.
Gargiulo P, Goldberg J, Romani B, Schiaffini R, Ciampalini P, Faulk WP. Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus. Clin Exp Immunol. 1999;118:30–4.CrossRefPubMedCentralPubMed
22.
Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation. 1999;68:241–6.CrossRefPubMed
23.
McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog Lipid Res. 2003;42:176–237.CrossRefPubMed
24.
Passam FH, Krilis SA. Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology. 2004;36:129–38.CrossRefPubMed
25.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.CrossRefPubMed
26.
Graves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353:1348–53.CrossRef
27.
Koike T. Antiphospholipid antibodies in arterial thrombosis. Ann Med. 2000;1:27–31.
28.
Stoheger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc Natl Acad Sci USA. 1993;90:6464–7.CrossRef
29.
Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol. 1989;20:52–67.CrossRefPubMed
30.
Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014;36(3):352–63.CrossRefPubMed
31.
Kwak JY, Gilman-Sachs A, Beaman KD, Beer AE. Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology. J Reprod Immunol. 1992;22:15–31.CrossRefPubMed
32.
Lockshim MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med. 2003;349:1177–9.CrossRef
33.
Derksen RHWM, Khamasta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 2004;50:1028–39.CrossRefPubMed
34.
Soulier JP, Boffa MC. Avortement repetition, thromboses, et anticoagulant circulant antithromboplastine. Nouv Presse Med. 1980;9:859–64.
35.
Branch DW, Silver RM. Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Lupus. 1996;5:409–13.PubMed
36.
El-Roeiy A, Gleicher N, Friberg J, Myers A. Correlation between peripheral blood and follicular fluid autoantibodies and impact on in vitro fertilization. Obstet Gynecol. 1987;70:163–70.PubMed
37.
Geva E, Amit A, Lerner-Geva L, Lessing JB, Yaron Y. Autoimmune disorders: another possible cause for in vitro fertilization and embryo transfer failure. Hum Reprod. 1995;10:2560–3.PubMed
38.
Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE. Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology. J Reprod Immunol. 1992;22:15–31.CrossRefPubMed
39.
Mardesic T, Ulcova-Gallova Z, Huttelova R, Muller P, Voboril J, Hulvert J. The influence of different types of antibodies on in vitro fertilization results. Am J Reprod Immunol. 2000;43:1–5.CrossRefPubMed
40.
Gleicher N. Antiphospholipid antibodies and reproductive failure: what they do and what they do not do; how to, and how not to treat. Hum Reprod. 1997;12:13–6.CrossRefPubMed
41.
Christiansen OB, Ulcova-Gallova Z, Mohapeloa H, Krauz V. Studies on associations between human leucocyte antigen (HLA) class II and antiphospholipid antibodies in Danish and Czech women with recurrent miscarriages. Hum Reprod. 1998;13:3326–31.CrossRefPubMed
42.
Ulcova-Gallova Z, Krauz V, Novakova P, Milichovska L, Micanova Z, Bibkova K, Sucha R, Turek J, Balvin M, Rokyta Z. Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol. 2005;54:112–7.CrossRefPubMed
43.
Dmowski WP, Rana N, Michalowska J. The effect of endometriosis, its stage and activity, and of autoantibodies on in vitro fertilization and embryo transfer rates. Fertil Steril. 1995;63:555–62.PubMed
44.
Ulcova-Gallova Z, Bouse V, Svabek L, Turek J, Rokyta Z. Endometriosis in reproductive immunology. Am J Reprod Immunol. 2002;47:269–74.CrossRefPubMed
45.
Ulcova-Gallova Z. Diagnosis infertility—the attack of immunity. 2nd ed. Prague: Grada; 2013. p. 1–99.
46.
Subrt I, Ulcova-Gallova Z, Bibkova K, Micanova Z, Hejnalova M, Cerna M. Recurrent pregnancy loss and frequency of eight antiphospholipid antibodies and genetic thrombophilic factors in Czech women. Am J Reprod Immunol. 2008;59(3):193–200.CrossRefPubMed
47.
Subrt I, Ulcova-Gallova Z, Cerna M, Hejnalova M, Slovanova J, Bibkova K, Micanova Z. Recurrent pregnancy loss, plasminogen activator inhibitor-1 (−675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women. Am J Reprod Immunol. 2013;70(1):54–8.CrossRefPubMed
48.
Rai RM, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with phospholipid antibodies. Br Med J. 1997;314:253–7.CrossRef
49.
Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169:1411–7.CrossRefPubMed
50.
Ulcova-Gallova Z, Krauz V, Rokyta Z. Six kinds of antiphospholipid antibodies in ovulatory cervical mucus and seminal plasma from couples with repeated miscarriages. Int J Fertil Womens Med. 2000;45(4):292–6.PubMed
51.
Hradecky L, Subrt I, Ulcova-Gallova Z. Urgent termination of pregnancy in pre-eclampsia and panel of antiphospholipid antibodies. Am J Reprod Immunol. 2009;62(6):412–7.CrossRefPubMed
52.
Mockova A, Ulcova-Gallova Z, Nahlovsky J, Lukasova V, Dort J, Bibkova K, Micanova Z. Occurrence of selected antiphospholipid antibodies in offspring born from mothers with autoimmunity. Lupus. 2012;21(7):793–5.CrossRefPubMed
53.
Ulcova-Gallova Z, Bibkova K, Micanova Z, Babcova K, Losan P. Moglicher Einfluss der verlangerten Einnahme hormonaler Kontrazeptiva auf eine Erhohung der Anti-Phospholipid-Antikorper-Konzentration bei infertilen Frauen. 2014 (Ready for publication).
Metadata
Title
The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience
Author
Zdenka Ulcova-Gallova
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Reproductive Medicine and Biology / Issue 2/2015
Print ISSN: 1445-5781
Electronic ISSN: 1447-0578
DOI
https://doi.org/10.1007/s12522-014-0196-y

Other articles of this Issue 2/2015

Reproductive Medicine and Biology 2/2015 Go to the issue

Minireview

Hormonal therapy for non-obstructive azoospermia: basic and clinical perspectives

Original Article

Clomiphene citrate affects the receptivity of the uterine endometrium

Review Article

Regulation of gonadotropin secretion by monitoring energy availability

Review Article

Autophagic activity as an indicator for selecting good quality embryos

Original Article

Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume